ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Factors Affecting Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03372655
Recruitment Status : Not yet recruiting
First Posted : December 14, 2017
Last Update Posted : December 14, 2017
Sponsor:
Information provided by (Responsible Party):
Nehal Refaat Mohammed, Assiut University

December 6, 2017
December 14, 2017
December 14, 2017
January 1, 2018
January 1, 2019   (Final data collection date for primary outcome measure)
Ten meter walking test [ Time Frame: 2018 - 2019 ]
Questionnaire
Same as current
No Changes Posted
Muscle strenght [ Time Frame: 2018- 2019 ]
Questionnaire
Same as current
Not Provided
Not Provided
 
Prognostic Factors Affecting Duchenne Muscular Dystrophy
Prognstic Factors Affecting Duchenne Muscular Dystrophy
Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy
Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Male patient diagnosed as duchenne muscular dystrophy by typical clinical picture&shooting serum CPK level & EMG study or biopsy
Duchenne Muscular Dystrophy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
82
Same as current
March 1, 2019
January 1, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • any male pt diagnosed as duchenne muscular dystrophy by typical clinical picture &shooting serum CPK level &EMG study or biopsy & age 10 to 18yrs old

Exclusion Criteria:

  • female patient ' age below 10 yrs old or above 18 yrs old .patient with autoimmune disease or malignancy
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
10 Years to 18 Years   (Child, Adult)
Not Provided
Contact: Nehal Refaat, Residant 01000242438 nehalrefaatmohammed@gmail.com
Not Provided
 
 
NCT03372655
PFADMD
Not Provided
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Nehal Refaat Mohammed, Assiut University
Assiut University
Not Provided
Not Provided
Assiut University
December 2017